Trovagene cf-NA interim results

|By:, SA News Editor

In what appears to be a hand-picked six-patient subset of a study of the prevalence of the BRAF V600E mutation in Erdheim-Chester disease, MD Anderson Cancer Center's Filip Janku finds that Trovagene's (TROV -2.4%) urine-based cell-free nucleic test for the mutation agrees with the six biopsy results. The theory is that the non-invasive diagnostic might be clinically useful considering that 60% of biopsies fail to provide enough tissue for testing.

The fact that the company has yet generate any revenue from the BRAF testing service it launched six months ago reinforces the embryonic nature of urine-based oncogene testing. There is much work to be done to validate its clinical usefulness.